Stoke Therapeutics
Presence
Stoke Therapeutics is one of the...
Stoke Therapeutics is a company listed under the stock ticker STOK (US).
Executives
View the org chart displaying its 19 main executives
Most searched biographies at Stoke Therapeutics
- Edward Kaye, Chief Executive Officer and Director
- Arthur Levin, Director
- Jennifer Burstein, Director
Popular executive movements at Stoke Therapeutics
- Stephen Tulipano, Chief Financial Officer, has left the company (posted on April 30 2024).
- Thomas Leggett has joined the company as Chief Financial Officer (posted on April 30 2024).
- Jason Hoitt has joined the company as Chief Commercial Officer (posted on April 18 2024).
Click here to view some more movements at Stoke Therapeutics
Create your alert
to follow the executive moves at Stoke Therapeutics.
Biotechnology
Stoke Therapeutics has 2,286 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Stoke Therapeutics
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference - Stoke Therapeutics
- Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome - Stoke Therapeut
- Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome - Stoke
- Press Releases - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome - Stoke Therapeutics
- Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference - Stoke Therapeutics
- View more press releases Close
Social media about Stoke Therapeutics
- Stoke Therapeutics on Wikipedia, Google News & Yahoo Finance
- Stoke Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Edward Kaye 
Call Stoke Therapeutics at +1 781...
